Extracorporeal photopheresis (ECP) has been shown to be a promising treatment for chronic graft-versus-host disease; however, only a few case reports are available that examine the effectiveness of ECP for bronchiolitis obliterans (BO) after allo-SCT. Because of the poor response to traditional therapies, ECP has been explored as a possible therapeutic option for severe BO after allo-SCT. Nine patients received ECP between July 2008 and August 2009 after a median follow-up of 23 months (range 9-93 months) post transplant. The primary indication for ECP was the development of BO in patients who had failed prior multidrug regimens. The median number of drugs used for BO management before ECP was 5 (range 2-7); this included immunosuppressive therapy. Six of nine (67%) patients responded to ECP after a median of 25 days (range 20-958 days). No ECP-related complications occurred. ECP seemed to stabilize rapidly declining pulmonary function tests in about two-thirds of patients with severe and heavily pretreated BO that developed after allo-SCT. This finding supports the need for a larger prospective study to confirm the impact of ECP on BO, and to consider earlier intervention with ECP to improve the outcome of BO after allo-SCT.
Introduction
Currently, more than 15 000-20 000 patients undergo allo-SCT annually throughout the world, with the number of long-term survivors increasing rapidly. As SCT becomes safer, more than 80% of patients living 2 years after allo-SCT will become long-term survivors. 1 In long-term follow-up after transplantation, the focus of care moves beyond cure of the original disease to the identification and treatment of chronic complications that can affect quality of life. Chronic graft-versus-host-disease (cGVHD) has attracted the most attention, especially the noninfectious pulmonary complication bronchiolitis obliterans (BO). Obstructive pulmonary function abnormality has been linked with cGVHD. 2, 3 Lung injury, a frequent complication after allo-SCT, and noninfectious pulmonary deaths account for a significant proportion of TRM. 4 Lifetime risk of chronic pulmonary dysfunction ranges from 30 to 60%. 5, 6 Extracorporeal photopheresis (ECP) has been shown to be a promising treatment for cGVHD. 7, 8 However, only a few case reports are available that examine the effectiveness of ECP for BO after allo-SCT. More recently, ECP has been reported as an effective treatment for lung transplantation complicated by BO. 9 Due to the poor response to traditional therapies, ECP has been increasingly used as a possible therapeutic option for severe BO after allo-SCT. Prospective studies of long-term survivors after allo-SCT with BO treated with ECP are lacking. Here we report one of the largest single-center case series using ECP in BO after allo-SCT. The aim of this study was to determine the clinical effectiveness of ECP in the treatment of BO, as measured by improvement in clinical status and pulmonary function tests (PFTs).
Patients and methods
Nine patients received ECP between July 2008 and August 2009 after a median follow-up of 23 months post transplant (range 9-93 months). The primary indication for ECP was symptomatic BO, which failed prior systemic immunosuppressive therapy as well as combination therapy with azithromycin (A), inhaled steroids (F) ± montelucast sodium (M) (FAM, F 220-440 mg inhalation twice daily, A 250 mg orally three times a week, M 10 mg orally once daily) (Tables 1 and 2 Records from these patients were reviewed to determine the impact of ECP on BO after allo-SCT in a study approved by the institutional review board. In an effort to provide a uniform definition of BO for clinical management and clinical trials, the proposed amended National Institutes of Health BO criteria for diagnosis of all our nonpathologically confirmed BO were used. 2, 3 In addition, all of our patients were clinically symptomatic secondary to progressive BO.
ECP treatment
Patients were treated on a weekly basis with two pheresis sessions a week. This was continued for 3-4 weeks and then decreased to an every 2-to 3-week interval. The goal was to get patients to an every 4-week frequency. Details of ECP treatment have been previously described. 7 ECP clinical response definition Clinical response to ECP was defined as symptomatic improvement, decreased dependency on supplemental oxygen (if the patient was requiring oxygen therapy for BO) and improvement in PFTs.
Results
Patient characteristics are summarized in Table 1 . All except one (aplastic anemia) patient received allo-SCT for hematological malignancies. The median age was 38 years (range 21-54 years), and five patients were women. Patients received allo-SCT between January 2002 and June 2008 (BMT ¼ 2; PBSC transplantation ¼ 7) from matched-related (n ¼ 5) or unrelated donor (n ¼ 4). The conditioning consisted of TBI-based myeloablative regimens in seven patients (non-TBI ¼ 2). GVHD prophylaxis consisted of calcineurin inhibitors and MTX or mycophenolate. Pre-SCT, only one patient had forced expiratory volume in 1 s (FEV1) o80% predicted. Grade II-IV acute GVHD occurred in eight patients, grade III in only one patient. All patients experienced cGVHD, three patients had five organ involvements (median 3, range 1-5) (Tables 1 and 2 ).
Pulmonary data
Median time to BO was 17 months post transplantation (range 5-46 months). The median numbers of drugs for BO management, including immunosuppressive therapy pre-ECP were 5 (range 2-7). Median time to ECP after diagnosis of BO was 17 months (range 5-46 months). Six of nine (67%) patients responded to ECP after a median of 25 days (range 20-958 days) (Figure 1) . Two of three patients who did not qualify as responders were symptomatically better. However, these patients had either stable or decreased forced expiratory volume in 1 s on ECP. We were unable to analyze the efficacy of ECP in subgroups because of small sample size. No ECP-related complications occurred in our case series. ECP seemed to stabilize rapidly declining PFTs in about two-thirds of patients in a subgroup of severe, heavily pretreated BO developing after allo-SCT ( Figure 1, Table 2 ).
Discussion
Our case series shows that the addition of ECP to commonly used regimens for BO results in more rapid improvement in patient symptoms and PFTs in an otherwise debilitating long-term complication of allo-SCT.
BO is a progressive, insidious and often fatal pulmonary complication that occurs after allo-SCT. 2, 3 Survival and treatment of patients with BO after allo-SCT has not improved over the last 20 years due to nonavailability of effective treatment. Challenges to the progress in medical management of BO include lack of relevant animal models, little knowledge about pathogenesis to direct effective targeted therapy and often a delay in diagnosis. The ability to detect BO in an earlier reversible phase despite close monitoring of PFT after allo-SCT is limited. Our data suggest early institution of ECP might help modify the natural history of BO in early phase. It will be interesting to see how many patients develop severe BO in the upcoming BMT-CTN study (protocol-0801) (http://www.bmtctn.net), a phase II/III randomized, multicenter trial comparing sirolimus plus prednisone, sirolimus/ECP plus prednisone and sirolimus/calcineurin inhibitor plus prednisone for the treatment of cGVHD, where ECP is being started as firstline therapy for cGVHD. If this study confirms ECP is an effective means of preventing or decreasing the severity of BO, the next step would be to consider a study using ECP as a GVHD prophylaxis in patients at high risk for developing BO. 5 Reports suggest that a forced expiratory volume in 1 s decline of 5% per year might identify a population at higher risk for poor outcome, because rapid airflow decline was also reported to be associated with significant attributable mortality rates of 9% at 3 years, 12% at 5 years and 18% at 10 years post-SCT. Moreover, mortality was much higher for the subpopulations of patients with Table 1 Patients characteristics (n ¼ 9)
No of patients 9 Age at transplant, range (median) 21-54 (38 years) Gender cGVHD (22% at 3 years, 27% at 5 years and 40% at 10 years). 3, 10 These are the group of patients who may be considered for early ECP in a clinical trials to reduce morbidity and mortality after allo-SCT.
More commonly, azithromycin, 11,12 inhaled steroids 13 and standard immunosuppressive therapy (including systemic steroids) have been used to treat BO. There have also been anecdotal reports using TNF blockade, 14 imatinib, 15 leukotrine inhibitors 16 and statins, 17 but very few patients with severe BO respond to these remedies. Sirolimus (an inhibitor of the mammalian target of rapamycin pathway) 18 and telomere activators have theoretical advantages over currently used regimen for treatment of BO. Short telomeres and mutations in telomerase have been linked to pulmonary fibrosis, 19 -21 a common finding in patients with end-stage pulmonary complications after allo-SCT. Sirolimus has been shown to be effective in GVHD prophylaxis after allo-SCT. 22 However, the prevalence of BO has not been known in these cohorts. The BMT-CTN study (protocol-0801) arm using sirolimus, ECP and steroid for cGVHD appears very attractive; this prospective study will reveal which treatment regimen is most effective in reducing the incidence and severity of BO.
Another potentially effective agent could be inhaled CsA, although there is no data in allo-SCT recipients. Data in lung transplantation have shown that inhaled CsA improved survival by reducing chronic graft rejection (considered equivalent to BO in allo-SCT recipients) with very high local immunosuppression and little additional systemic toxicity. 23, 24 Challenges to the progress of medical management of BO include nonavailability of effective therapy. Our data showed early encouraging results using ECP in advanced refractory BO. However, the optimal time point to initiate ECP, duration of ECP and the best combination approach are unknown. Results of our study are limited by its retrospective nature, small sample size and short followup. Clinical and PFT improvement after ECP in our series could also be a delayed response to prior multidrugs regimen or a synergistic effect of ECP. We suggest that these findings be validated in larger prospective trials of early intervention with ECP, and possibly in combination with other effective agents for patients with symptomatic BO. P r e -S C T P r e -E C P L a t e s t 
